PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Parametric Eduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 1

NOV 0 6 2006

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

(Use as many sneets as necessary

Col	mplete if Known	
Application Number	10/560,069	
Filing Date	December 10, 2005	
First Named Inventor	Stephen John Kent	
Art Unit	Unassigned	
Examiner Name	Unassigned	
Attorney Docket Number	23558-007	

			U. S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (ff known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-		-	
	-	US-			
		US-		·	
		US-			
	-	US-			
		US-			
		US-			
-		US-			
	<u> </u>	US-			
<u>-</u>		US-			
		US-		,	
		US-			
		US-	1		
		US-	† · · · · · · · · · · · · · · · · · · ·		

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T⁵
		WO 02/062375 A1	08-15-2002	Merck Patent GMBH		
		WO 01/40281 A2	06-07-2001	Thromb-X N.V.		
		WO 01/019408 A1	03-22-2001	Zycos Inc.		
		WO 01/16163 A2	03-08-2001	Euro-Diagnostica AB		
		WO 01/07625 A2	02-01-2001	Cornell Research		
		WO 94/03487	02-17-97	Jean-François ZAGURY		

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number 10/560.069 Filing Date December 10, 2005 INFORMATION DISCLOSURE First Named Inventor Stephen John Kent STATEMENT BY APPLICANT Art Unit Unassigned

(Use as many sheets as necessary)

Examiner Name Unassigned Attorney Docket Number 23558-007 Sheet 2

Examiner	Cite No.1	Document Number	U. S. PATENT De Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant
Initials*	No.1	D. 1 MM-DD-YYYY Number-Kind Code ^{2 (ff known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
		US-			
		US-			*
		US-	· · · · · · · · · · · · · · · · · · ·		
		US-			
		US-	<u> </u>		
		US-			
		US-		1010	
		US-			
		US-			
		US-	 		
		US-			
		us-			

		FORE	IGN PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	6
		Country Code ³ Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	_T
		WO 02/36748 A2	05-10-2002	Nexell Therapeutics, Inc.		
						L
						L
						L

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	NFORMATION DISCLOSURE STATEMENT BY APPLICANT			Complete if Known	
Gubolila	10 10 10 10 10 10 10 10 10 10 10 10 10 1			Application Number	10/560,069
INF	ORMATION	I DIS	CLOSURE	Filing Date	December 10, 2005
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Stephen John Kent
	llise as many she	ets as n	Application Number 10/560,069 DISCLOSURE Filing Date December 10, 2005 APPLICANT Stephen John Kent Art Unit Unassigne		
	(OSC as many sine	45 //		Examiner Name	Unassigned
Sheet	3	of	4	Attorney Docket Number	23558-007

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Holden T. Maecker, et al., "Use of Overlapping Peptide MixturesCytometry", Journal of Immunological Methods, 2001, pp. 27-40, Vol. 255, Elsevier Science B.V	
		Anthony HC. Choi, et al., "Functional Mapping of Protective EpitopesDifferent Haplotypes", Vaccine, 2003, pp. 761-767, Vol. 21, Elsevier Science B.V	
		Vishwa Deo Trivedi, et al., "The LLSGIV stretch of the N-terminalPeptide, T20", Protein Engineering, 2003, pp. 311-317, Vol. 16, No. 4, Oxford University Press	
		Birgit Drabner, et al., "Identification of T helper cell-recognizedfilarial nematode Onchocerca volvulus", Vaccine, 2002, pp. 3685-3694, Vol. 20, Elsevier Science Ltd.	
		Vesna Blazevic, et al., "Helper T-Cell Recognition of HIV-1 Tat Synthetic Peptides", Journal of Acquired Immune Deficiency Syndrome, 1993, pp. 881-890, Raven Press, New York	
"		J. Marttila, et al., "Definition of three minimal T helper cell epitopes of rubella virus E1 glycoprotein", Clin Exp Immunol, 1996, pp. 394-397, Vol. 104, Blackwell Science	
		Carel A. van Baalen, et al., "Fine-specificity of cytotoxic T lymphocytes which immunodeficiency virus type 1", Journal of General Virology, 1996, pp. 1659-1665, Vol. 77	
		Adriana Albini, et al., "Identification of a Novel Domain of HIV Tat involved in Monocyte Chemotaxis*", The Journal of Biological Chemistry, 1998, pp. 15895-15900, Vol. 273	
		Peggy A. Wentworth, et al., "Epitopes recognized by HIV-SF2 nef-specificHIV-1-uninfected donors", Vaccine, 1994, pp. 117-128, Vol. 12, Butterworth-Heinemann Ltd.	
		S.M. Lonning, et al., "Gag Protein Epitopes RecognizedCarrier Horses", Journal of Virology, 1999, pp. 4257-4265, Vol. 73, No. 5, American Society for Microbiology	

Examiner	D	Date	
Signature	C	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTO/SB/08B (07-05)

ostitute for form 1449/PTO		
	Complete if Known	
Under the Paperwork Reduction Act of 1995, no persons are	e required to respond to a collection of information unless it contains a valid OMB cont	rol number.
	U.S. Patent and Trademark Office; U.S. DEPARTMENT OF C	
	Approved for use through 07/31/2006, OMB	0651-003

Sub **Application Number** 10/560,069 INFORMATION DISCLOSURE Filing Date December 10, 2005 STATEMENT BY APPLICANT **First Named Inventor** Stephen John Kent Art Unit Unassigned (Use as many sheets as necessary) **Examiner Name** Unassigned Attorney Docket Number Sheet 4 4 23558-007 of

the state of the s	
Initials* No.¹ the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-iss number(s), publisher, city and/or country where published. Carel A. van Baalen, et al., "Selective in vitro expansion of HLAand precursor frequencial AIDS, 1993, pp. 781-786, Vol. 7, No. 6, Current Science Ltd. ISSN 0269-9370. Petra A. M. Warmerdam, et al., "Elimination of a Human T-celland Computer Modeling Thromb Haemost, 2002, pp. 666-673, Vol. 87, 2002 Schattauer GmbH, Stuttgart. Ivan Stratov, et al., "Vaccines and VCaccine Strategies Against HIV", Curren Drug Targets, 2004, pp. 71-88, Vol. 5, 2004 Bentham Science Publishers Ltd. Bradley H. Edwards, et al., "Magnitude of Functional CD8+Viral Load in Plasma", Journ	
AIDS, 1993, pp. 781-786, Vol. 7, No. 6, Current Science Ltd. ISSN 0269-9370. Petra A. M. Warmerdam, et al., "Elimination of a Human T-celland Computer Modeling Thromb Haemost, 2002, pp. 666-673, Vol. 87, 2002 Schattauer GmbH, Stuttgart. Ivan Stratov, et al., "Vaccines and VCaccine Strategies Against HIV", Curren Drug Targets, 2004, pp. 71-88, Vol. 5, 2004 Bentham Science Publishers Ltd. Bradley H. Edwards, et al., "Magnitude of Functional CD8+Viral Load in Plasma", Journ	
Thromb Haemost, 2002, pp. 666-673, Vol. 87, 2002 Schattauer GmbH, Stuttgart. Ivan Stratov, et al., "Vaccines and VCaccine Strategies Against HIV", Curren Drug Targets, 2004, pp. 71-88, Vol. 5, 2004 Bentham Science Publishers Ltd. Bradley H. Edwards, et al., "Magnitude of Functional CD8+Viral Load in Plasma", Journ	,
Drug Targets, 2004, pp. 71-88, Vol. 5, 2004 Bentham Science Publishers Ltd Bradley H. Edwards, et al., "Magnitude of Functional CD8+Viral Load in Plasma", Journ	

Examiner		Date	
Signature	/Amy Juedes/	Considered	06/01/2009

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.